Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients with Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab
Averaged mean change from baseline in Myasthenia GravisActivities of Daily Living (MG-ADL) total score over Weeks 8 to 12 between Arms 1 and 2. Averaged mean percent change from baseline in total IgG over Weeks 8 to 12 between Arms 1 and 2.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.